In order to evaluate the potential synergistic antagonism of PD-1 and MET in a more clinically relevant model with a tumor microenvironment mirroring the original tumor [24,25,26,27,28], we next performed drug testing in PD-1+/MET+ PDAC PDOs hPT1 and hPT4. Here, CDH17 is linked to neoplasm.